Missy Buco, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 142a Danielson Pike, Foster, RI 02825 Phone: 401-647-3702 |
Ms. Cathleen Dee Jaderquist-bassett, NPP Nurse Practitioner - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 142a Danielson Pike, Foster, RI 02825 Phone: 401-647-3702 Fax: 401-647-5380 |
News Archive
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
Researchers have discovered a way to better predict progression of Alzheimer's disease. By imaging microglial activation levels with positron emission tomography, researchers were able to better predict progression of the disease than with beta-amyloid PET imaging, according to a study published in the April issue of the Journal of Nuclear Medicine.
VIVUS, Inc. today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009.
The National Organization for Rare Disorders (NORD) announced that Discovery Health and its new program, DISEASE DETECTIVES, will serve as media and program partners for Rare Disease Day on February 28, 2010.
Obesity has been linked to "letter" changes at many different sites in the genome, yet these differences do not fully explain the variation in people's body mass index (BMI) or why some overweight people develop health complications while others don't.
› Verified 3 days ago